Analysis of antiglobulin (HAMA) response in a group of patients with B-lympkocytic malignancies treated with 131I-Lym-1

Gerald L Denardo, L. A. Kroger, G. R. Mirick, K. R. Lamborn, S. J. De Nardo

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Host development of human anti-mouse antibodies (HAMA) in response to administered antibodies has been reported as a problem for antibody imaging and therapy However; radioimmunotherapy has been shown to be effective in patients with B-cell malignancies because their immunodeficient state precludes or delays development of a HAMA response to mouse antibodies. Baseline HAMA activity was assayed in 60 patients with B-lymphocytic non-Hodgkin's lymphoma or chronic lymphocytic leukemia and sequentially in 43 patients who were subsequently treated with radiolabeled Lym-1 antibody. Pre-existing 'HAMA' activity was found in 3 (5%) of the 60 patients screened for treatment consideration. The incidence of development of HAMA in the 43 patients treated with multiple doses of radiolabebed Lym-1 antibody was 12 (28%). There was no evidence for an anaphylactoid or related response in the HAMA positive patients. HAMA activity interrupted therapy in 14% of the patients (6 of 43) but did not preclude therapeutic responses to radiolabeled Lym-1 therapy. Median survival for the HAMA positive patients was longer (18 months) than for those who did not develop HAMA activity (9 months).

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalInternational Journal of Biological Markers
Volume10
Issue number2
StatePublished - 1995

Fingerprint

Antibody Formation
Anti-Idiotypic Antibodies
Antibodies
Neoplasms
Human Development
Radioimmunotherapy
Therapeutics
B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
B-Lymphocytes
Survival
Incidence
Cells
Imaging techniques

Keywords

  • Antiglobulin
  • Chronic lymphocytic leukemia
  • HAMA
  • Lym-1
  • Lymphoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Analysis of antiglobulin (HAMA) response in a group of patients with B-lympkocytic malignancies treated with 131I-Lym-1. / Denardo, Gerald L; Kroger, L. A.; Mirick, G. R.; Lamborn, K. R.; De Nardo, S. J.

In: International Journal of Biological Markers, Vol. 10, No. 2, 1995, p. 67-74.

Research output: Contribution to journalArticle

@article{bc4dce35cf304b379d6a9ba2c278539e,
title = "Analysis of antiglobulin (HAMA) response in a group of patients with B-lympkocytic malignancies treated with 131I-Lym-1",
abstract = "Host development of human anti-mouse antibodies (HAMA) in response to administered antibodies has been reported as a problem for antibody imaging and therapy However; radioimmunotherapy has been shown to be effective in patients with B-cell malignancies because their immunodeficient state precludes or delays development of a HAMA response to mouse antibodies. Baseline HAMA activity was assayed in 60 patients with B-lymphocytic non-Hodgkin's lymphoma or chronic lymphocytic leukemia and sequentially in 43 patients who were subsequently treated with radiolabeled Lym-1 antibody. Pre-existing 'HAMA' activity was found in 3 (5{\%}) of the 60 patients screened for treatment consideration. The incidence of development of HAMA in the 43 patients treated with multiple doses of radiolabebed Lym-1 antibody was 12 (28{\%}). There was no evidence for an anaphylactoid or related response in the HAMA positive patients. HAMA activity interrupted therapy in 14{\%} of the patients (6 of 43) but did not preclude therapeutic responses to radiolabeled Lym-1 therapy. Median survival for the HAMA positive patients was longer (18 months) than for those who did not develop HAMA activity (9 months).",
keywords = "Antiglobulin, Chronic lymphocytic leukemia, HAMA, Lym-1, Lymphoma, Radioimmunotherapy",
author = "Denardo, {Gerald L} and Kroger, {L. A.} and Mirick, {G. R.} and Lamborn, {K. R.} and {De Nardo}, {S. J.}",
year = "1995",
language = "English (US)",
volume = "10",
pages = "67--74",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing",
number = "2",

}

TY - JOUR

T1 - Analysis of antiglobulin (HAMA) response in a group of patients with B-lympkocytic malignancies treated with 131I-Lym-1

AU - Denardo, Gerald L

AU - Kroger, L. A.

AU - Mirick, G. R.

AU - Lamborn, K. R.

AU - De Nardo, S. J.

PY - 1995

Y1 - 1995

N2 - Host development of human anti-mouse antibodies (HAMA) in response to administered antibodies has been reported as a problem for antibody imaging and therapy However; radioimmunotherapy has been shown to be effective in patients with B-cell malignancies because their immunodeficient state precludes or delays development of a HAMA response to mouse antibodies. Baseline HAMA activity was assayed in 60 patients with B-lymphocytic non-Hodgkin's lymphoma or chronic lymphocytic leukemia and sequentially in 43 patients who were subsequently treated with radiolabeled Lym-1 antibody. Pre-existing 'HAMA' activity was found in 3 (5%) of the 60 patients screened for treatment consideration. The incidence of development of HAMA in the 43 patients treated with multiple doses of radiolabebed Lym-1 antibody was 12 (28%). There was no evidence for an anaphylactoid or related response in the HAMA positive patients. HAMA activity interrupted therapy in 14% of the patients (6 of 43) but did not preclude therapeutic responses to radiolabeled Lym-1 therapy. Median survival for the HAMA positive patients was longer (18 months) than for those who did not develop HAMA activity (9 months).

AB - Host development of human anti-mouse antibodies (HAMA) in response to administered antibodies has been reported as a problem for antibody imaging and therapy However; radioimmunotherapy has been shown to be effective in patients with B-cell malignancies because their immunodeficient state precludes or delays development of a HAMA response to mouse antibodies. Baseline HAMA activity was assayed in 60 patients with B-lymphocytic non-Hodgkin's lymphoma or chronic lymphocytic leukemia and sequentially in 43 patients who were subsequently treated with radiolabeled Lym-1 antibody. Pre-existing 'HAMA' activity was found in 3 (5%) of the 60 patients screened for treatment consideration. The incidence of development of HAMA in the 43 patients treated with multiple doses of radiolabebed Lym-1 antibody was 12 (28%). There was no evidence for an anaphylactoid or related response in the HAMA positive patients. HAMA activity interrupted therapy in 14% of the patients (6 of 43) but did not preclude therapeutic responses to radiolabeled Lym-1 therapy. Median survival for the HAMA positive patients was longer (18 months) than for those who did not develop HAMA activity (9 months).

KW - Antiglobulin

KW - Chronic lymphocytic leukemia

KW - HAMA

KW - Lym-1

KW - Lymphoma

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029010764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029010764&partnerID=8YFLogxK

M3 - Article

C2 - 7561241

AN - SCOPUS:0029010764

VL - 10

SP - 67

EP - 74

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 2

ER -